Deep vein thrombosis, also known as DVT refers to the formation of a thrombus in a deep vein in the leg. A thrombus is a blood clot. Deep vein thrombosis tends to occur in leg veins, such as the popliteal or femoral veins, as well as deep veins within the pelvis. In some cases, as with Paget-SchrÃ tter disease, they may form in the veins of the arm. If the thrombus breaks off, it is known as an embolus - a piece of blood clot - and can make its way to the lung, resulting in a pulmonary embolism. In other contexts, an embolus may also refer to a piece of fat or an air bubble. Deep vein thrombosis and pulmonary embolism are two parts of the disease known as venous thromboembolism. Some people may develop DVT and not be aware of it; there will be no symptoms. Commonly, though, the patient will experience pain, swelling, redness, tenderness and warmth in the affected area;
"Economy Class Syndrome" is a myth, your risk of developing a blood clot during a long-distance economy trip by plane is not higher than in first class, researchers report in an article published in Chest. The American College of Chest Physicians (ACCP) has issued new evidence-based guidelines which address some of the risk factors linked to DVT ( deep vein thrombosis ) - it says that there is no compelling evidence linking economy class air travel to the development of DVT. The risk factors that the experts addressed include sitting in a window seat, being old, pregnancy, and using oral contraceptives. The new guidelines are called Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Guideline co-author Mark Crowther, MD, Department of Medicine, McMaster University, Hamilton, Ontario, Canada, said: "Traveling in economy class does not increase your risk for developing a blood clot, even during long-distance travel;
Blood tests have been a mainstay of diagnostic medicine since the late 19th century, offering a wealth of information concerning health and disease. Nevertheless, blood derived from the human umbilical cord has yet to be fully mined for its vital health information, according to Rolf Halden, a researcher at Arizona State University's Biodesign Institute. In a new study appearing in the journal Environmental Health Perspectives, Halden's team performs detailed analyses of umbilical cord blood (UCB), identifying a total of 1, 210 proteins using mass spectroscopy. The findings represent a 6-fold increase in the number UCB proteins thus far described - a significant advance: "Mapping of the full spectrum of proteins detectable in cord blood is the first, crititcal step in the discovery of biomarkers to improve human health, " Halden says.
Two studies published in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM. The combination of bortezomib, cyclophosphamide, and dexamethasone (CyBorD, or CVD) is a recently discovered but already widely used MM treatment regimen that produces rapid and profound responses. Because of its success in MM, recent investigations have explored the use of this regimen as a potential therapy for AL amyloidosis, since those with the disease have few treatment options.
The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologis t, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to another commonly used anticoagulant, warfarin. The study was conducted by a team of Kaiser Permanente researchers from Colorado, Oregon, Washington and Northern California, Dana-Farber Cancer Institute and Group Health Research Institute. Venous thromboembolism, or blood clots, are common and serious complications in cancer patients.